Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Feb 13 2023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

By Admin|2023-02-12T19:53:01-05:00February 13th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic ...

Feb 8 2023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

By Admin|2023-02-08T04:58:45-05:00February 8th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...

Jan 24 2023

Halberd Agrees to Animal Testing at Mississippi State University

By Admin|2023-01-23T17:04:28-05:00January 24th, 2023|Investor News, Medical, News, Press Releases|0 Comments

College of Veterinary Medicine to conduct testing Jackson Center, PA January 24, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) has agreed to conduct animal testing at Mississippi State University’s (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will ...

Jan 3 2023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

By Admin|2023-01-02T20:07:25-05:00January 3rd, 2023|Featured, Investor News, Press Releases, Update Letter|0 Comments

Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. ...

Dec 6 2022

Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication

By Admin|2022-12-05T19:18:54-05:00December 6th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Halberd’s method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. Jackson Center, PA December 6, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication ...

Nov 14 2022

Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals

By Admin|2022-11-14T10:09:21-05:00November 14th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Accelerated Sales of HALB's Patented Products through newly formed “The Hamden Group” Jackson Center, PA, November 14, 2022 – Halberd Corporation (OTC-PINK: HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the ...

Oct 18 2022

Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minutes

By Admin|2022-10-17T20:12:29-04:00October 18th, 2022|Investor News, Medical, News, Press Releases|1 Comment

Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases Jackson Center, PA, October 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has successfully eliminated various antibiotic resistant bacteria from buffer solution , in-vitro, through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria. The combined ...

Oct 12 2022

Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum

By Admin|2022-10-11T20:09:20-04:00October 12th, 2022|Investor News, News, Press Releases, Uncategorized|0 Comments

Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Jackson Center, PA, October 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd’s ...

Sep 27 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

By Admin|2022-09-26T21:24:04-04:00September 27th, 2022|Featured, Investor News, News, Press Releases|1 Comment

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...

Aug 23 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

By Admin|2022-08-22T20:05:56-04:00August 23rd, 2022|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the ...

Previous 345 Next